Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Assets (2022 - 2025)

Historic Current Assets for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $272.4 million.

  • Stoke Therapeutics' Current Assets rose 742.28% to $272.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.4 million, marking a year-over-year increase of 742.28%. This contributed to the annual value of $232.8 million for FY2024, which is 808.82% up from last year.
  • Per Stoke Therapeutics' latest filing, its Current Assets stood at $272.4 million for Q3 2025, which was up 742.28% from $270.0 million recorded in Q2 2025.
  • Stoke Therapeutics' Current Assets' 5-year high stood at $375.7 million during Q1 2025, with a 5-year trough of $193.3 million in Q1 2024.
  • Its 4-year average for Current Assets is $264.0 million, with a median of $264.6 million in 2022.
  • As far as peak fluctuations go, Stoke Therapeutics' Current Assets plummeted by 2847.92% in 2024, and later surged by 9440.49% in 2025.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Current Assets stood at $244.1 million in 2022, then fell by 11.77% to $215.3 million in 2023, then grew by 8.09% to $232.8 million in 2024, then rose by 17.05% to $272.4 million in 2025.
  • Its last three reported values are $272.4 million in Q3 2025, $270.0 million for Q2 2025, and $375.7 million during Q1 2025.